{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:41:32Z","timestamp":1759405292845,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.06.023","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T21:30:15Z","timestamp":1655155815000},"page":"4318-4321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Receptor-enhanced immunogenicity of anthrax protective antigen is primarily mediated by capillary morphogenesis Protein-2"],"prefix":"10.1016","volume":"40","author":[{"given":"Anita","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-8883","authenticated-orcid":false,"given":"Mahtab","family":"Moayeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Mocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"O'Mard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Leppla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drusilla L.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.06.023_b0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mib.2003.12.001","article-title":"The roles of anthrax toxin in pathogenesis","volume":"7","author":"Moayeri","year":"2004","journal-title":"Curr Opin Microbiol"},{"issue":"32","key":"10.1016\/j.vaccine.2022.06.023_b0010","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.023_b0015","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.023_b0020","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/CVI.00469-14","article-title":"Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques","volume":"21","author":"Chen","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.023_b0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","article-title":"Anthrax toxin","volume":"19","author":"Collier","year":"2003","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.023_b0030","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41564-020-0782-1","article-title":"Anthrax lethal factor cleaves regulatory subunits of phosphoinositide-3 kinase to contribute to toxin lethality","volume":"5","author":"Mendenhall","year":"2020","journal-title":"Nat Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.023_b0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142728","article-title":"Anthrax toxin: receptor binding, internalization, pore formation, and translocation","volume":"76","author":"Young","year":"2007","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.023_b0040","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00209-18","article-title":"Role of the antigen capture pathway in the induction of a neutralizing antibody response to anthrax protective antigen","volume":"9","author":"Verma","year":"2018","journal-title":"mBio"},{"issue":"30","key":"10.1016\/j.vaccine.2022.06.023_b0045","doi-asserted-by":"crossref","first-page":"12424","DOI":"10.1073\/pnas.0905409106","article-title":"Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo","volume":"106","author":"Liu","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"42","key":"10.1016\/j.vaccine.2022.06.023_b0050","doi-asserted-by":"crossref","first-page":"22021","DOI":"10.1074\/jbc.M116.753301","article-title":"Anthrax toxin protective antigen variants that selectively utilize either the CMG2 or TEM8 receptors for cellular uptake and tumor targeting","volume":"291","author":"Chen","year":"2016","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.023_b0055","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00174-12","article-title":"Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant","volume":"19","author":"Wagner","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.023_b0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/CVI.00513-09","article-title":"Comparison of three anthrax toxin neutralization assays","volume":"17","author":"Ngundi","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.023_b0065","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00556-19","article-title":"Binding of the von Willebrand factor a domain of capillary morphogenesis Protein 2 to anthrax protective antigen vaccine reduces immunogenicity in mice","volume":"5","author":"de Oliveira","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2022.06.023_b0070","doi-asserted-by":"crossref","first-page":"e7946","DOI":"10.1371\/journal.pone.0007946","article-title":"Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein","volume":"4","author":"Hu","year":"2009","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.023_b0075","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1128\/IAI.01718-07","article-title":"Both CD4+ and CD8+ T cells respond to antigens fused to anthrax lethal toxin","volume":"76","author":"Shaw","year":"2008","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:17:19Z","timestamp":1759403839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":15,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X22007708"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Receptor-enhanced immunogenicity of anthrax protective antigen is primarily mediated by capillary morphogenesis Protein-2","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}